{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:40:28Z","timestamp":1780072828552,"version":"3.54.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI152772"],"award-info":[{"award-number":["R01AI152772"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["32FP30_207285"],"award-info":[{"award-number":["32FP30_207285"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["324730_207957"],"award-info":[{"award-number":["324730_207957"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIDRZ"},{"name":"Lighthouse Trust"},{"name":"IeDEA-SA"},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics of the National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["U01AI069924"],"award-info":[{"award-number":["U01AI069924"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with human immunodeficiency virus (PWH) on first-line, nonnucleoside reverse-transcriptase inhibitor\u2013based antiretroviral therapy (ART) were routinely switched to tenofovir-lamivudine-dolutegravir. We examined virologic outcomes and drug resistance in ART programs in Malawi, where switching was irrespective of viral load, and Zambia, where switching depended on a viral load &amp;lt;1000\u2005copies\/mL in the past year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the risk of viremia (\u2265400\u2005copies\/mL) at 1 and 2 years by viral load at switch and between countries using exact methods and logistic regression adjusted for age and sex. We performed HIV-1 pol Sanger sequencing on plasma samples with viral load \u22651000\u2005copies\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2832 PWH were eligible (Malawi 1422, Zambia 1410); the median age was 37 years, and 2578 (91.0%) were women. At switch, 77 (5.4%) were viremic in Malawi and 42 (3.0%) in Zambia (P = .001). Viremia at switch was associated with viremia at 1 year (adjusted odds ratio (OR), 6.15; 95% confidence interval [CI], 3.13\u201311.4) and 2 years (7.0; 95% CI, 3.73\u201312.6). Viremia was less likely in Zambia than in Malawi at 1 year (OR, 0.55; 0.32\u20130.94) and 2 years (OR, 0.33; 0.18\u20130.57). Integrase sequencing was successful for 79 of 113 eligible samples. Drug resistance mutations were found in 5 PWH (Malawi 4, Zambia 1); 2 had major mutations (G118R, E138K, T66A and G118R, E138K) leading to high-level dolutegravir resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Restricting switching to dolutegravir-based ART to PWH with a viral load &amp;lt;1000\u2005copies\/mL may reduce subsequent viremia and, consequently, the emergence of dolutegravir drug resistance mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov (NCT04612452).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae261","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T19:45:28Z","timestamp":1717098328000},"page":"120-128","source":"Crossref","is-referenced-by-count":17,"title":["Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia"],"prefix":"10.1093","volume":"80","author":[{"given":"Veronika Whitesell","family":"Skrivankova","sequence":"first","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Huwa","sequence":"additional","affiliation":[{"name":"Lighthouse Trust , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Muula","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Research in Zambia , Lusaka ,","place":["Zambia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geldert D","family":"Chiwaya","sequence":"additional","affiliation":[{"name":"Lighthouse Trust , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esau","family":"Banda","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Research in Zambia , Lusaka ,","place":["Zambia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Buleya","sequence":"additional","affiliation":[{"name":"Lighthouse Trust , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Chihota","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Research in Zambia , Lusaka ,","place":["Zambia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chintedza","sequence":"additional","affiliation":[{"name":"Lighthouse Trust , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Bolton","sequence":"additional","affiliation":[{"name":"Centre for Infectious Disease Research in Zambia , Lusaka ,","place":["Zambia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannock","family":"Tweya","sequence":"additional","affiliation":[{"name":"Lighthouse Trust , Lilongwe ,","place":["Malawi"]},{"name":"International Training and Education Center for Health (I-TECH) , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thokozani","family":"Kalua","sequence":"additional","affiliation":[{"name":"Center for International Health, Education, and Biosecurity (Ciheb) at University of Maryland, Baltimore School of Medicine (UMB) , Lilongwe ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hossmann","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]},{"name":"Diabetes Center Berne , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Institute of Medical Virology, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]},{"name":"Department of Infectious Diseases, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7462-5132","authenticated-orcid":false,"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University of Bern , Bern ,","place":["Switzerland"]},{"name":"Population Health Sciences, Bristol Medical School, University of Bristol , Bristol ,","place":["United Kingdom"]},{"name":"Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Lessells","sequence":"additional","affiliation":[{"name":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) , School of Laboratory Medicine & Medical Sciences, University of KwaZulu-Natal, Durban ,","place":["South Africa"]},{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA) , University of KwaZulu-Natal, Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"2025121707023872300_ciae261-B1"},{"key":"2025121707023872300_ciae261-B2","volume-title":"WHO Update of recommendations on first- and second-line antiretroviral regimens","year":"2019"},{"key":"2025121707023872300_ciae261-B3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciu221","article-title":"Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection","volume":"59","author":"Osterholzer","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"Lancet HIV"},{"key":"2025121707023872300_ciae261-B5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121707023872300_ciae261-B6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"NAMSAL ANRS 12313 Study Group","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121707023872300_ciae261-B7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2025121707023872300_ciae261-B8","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","article-title":"Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial","volume":"9","author":"Paton","year":"2022","journal-title":"Lancet HIV"},{"key":"2025121707023872300_ciae261-B9","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1097\/QAD.0000000000003068","article-title":"Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial","volume":"35","author":"Jamieson","year":"2021","journal-title":"AIDS"},{"key":"2025121707023872300_ciae261-B10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s41669-021-00275-6","article-title":"Cost-utility analysis of dolutegravir- versus efavirenz-based regimens as a first-line treatment in adult HIV\/AIDS patients in Ethiopia","volume":"5","author":"Belay","year":"2021","journal-title":"PharmacoEconomics Open"},{"key":"2025121707023872300_ciae261-B11","author":"WHO"},{"key":"2025121707023872300_ciae261-B12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/cid\/cis254","article-title":"Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies","volume":"54","author":"Hamers","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B13","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"2025121707023872300_ciae261-B14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciad390","article-title":"Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho","volume":"77","author":"Tschumi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B15","doi-asserted-by":"crossref","first-page":"e1003037","DOI":"10.1371\/journal.pmed.1003037","article-title":"Virological suppression and clinical management in response to viremia in South African HIV treatment program: a multicenter cohort study","volume":"17","author":"Hermans","year":"2020","journal-title":"PLoS Med"},{"key":"2025121707023872300_ciae261-B16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/QAD.0000000000002470","article-title":"Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa","volume":"34","author":"Salou","year":"2020","journal-title":"Aids"},{"key":"2025121707023872300_ciae261-B17","doi-asserted-by":"crossref","first-page":"e035246","DOI":"10.1136\/bmjopen-2019-035246","article-title":"International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012\u20132019","volume":"10","author":"Chammartin","year":"2020","journal-title":"BMJ Open"},{"key":"2025121707023872300_ciae261-B18","author":"Lighthouse Trust"},{"key":"2025121707023872300_ciae261-B19","author":"Centre for Infectious Disease Research in Zambia"},{"key":"2025121707023872300_ciae261-B20","author":"Malawi Ministry of Health and Population"},{"key":"2025121707023872300_ciae261-B21"},{"key":"2025121707023872300_ciae261-B22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025121707023872300_ciae261-B23","author":"KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP)"},{"key":"2025121707023872300_ciae261-B24","doi-asserted-by":"crossref","first-page":"eadn4168","DOI":"10.1126\/science.adn4168","article-title":"Investing in Africa's scientific future","volume":"383","author":"de Oliveira","year":"2024","journal-title":"Science"},{"key":"2025121707023872300_ciae261-B25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B26","author":"Stanford University"},{"key":"2025121707023872300_ciae261-B27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/biom.12231","article-title":"Combining one-sample confidence procedures for inference in the two-sample case","volume":"71","author":"Fay","year":"2015","journal-title":"Biometrics"},{"key":"2025121707023872300_ciae261-B28","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2021"},{"key":"2025121707023872300_ciae261-B29","author":"2025 AIDS TARGETS\u2014UNAIDS"},{"key":"2025121707023872300_ciae261-B30","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025121707023872300_ciae261-B31","author":"World Health Organization"},{"key":"2025121707023872300_ciae261-B32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1186\/s12879-021-06851-9","article-title":"Patient experiences of switching from efavirenz- to dolutegravir-based antiretroviral therapy: a qualitative study in Uganda","volume":"21","author":"Twimukye","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025121707023872300_ciae261-B33","doi-asserted-by":"crossref","first-page":"e00922-17","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"MBio"},{"key":"2025121707023872300_ciae261-B34","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"2025121707023872300_ciae261-B35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med"},{"key":"2025121707023872300_ciae261-B36","first-page":"285","article-title":"Brief report: virologic impact of the dolutegravir transition: prospective results from the Multinational African Cohort Study","volume":"91","author":"Esber","year":"2022","journal-title":"JAIDS"},{"key":"2025121707023872300_ciae261-B37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciab1006","article-title":"Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with human immunodeficiency virus treatment outcomes in sub-Saharan Africa","volume":"75","author":"Romo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B38","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciae185","article-title":"Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho","volume":"79","author":"Tschumi","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025121707023872300_ciae261-B39","doi-asserted-by":"crossref","first-page":"ofaa202","DOI":"10.1093\/ofid\/ofaa202","article-title":"Emergent resistance to dolutegravir among INSTI-na\u00efve patients on first-line or second-line antiretroviral therapy: a review of published cases","volume":"7","author":"Cevik","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae261\/58162850\/ciae261.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/120\/58162850\/ciae261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/120\/58162850\/ciae261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:02:50Z","timestamp":1765972970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/120\/7689381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,7]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae261","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,6,7]]}}}